Introduction to Gene Therapy: A Clinical Aftermath

Methods in Molecular Biology

Volumn 737, Issue , 2011, Pages 27-44

  Denèfle, Patrice P ^a  

^a IPSEN   (France)

Author keywords

Clinical trials; Ex vivo gene therapy; Gene therapy; Local delivery; Systemic delivery; Viral and nonviral approaches

Indexed keywords

LIPOPROTEIN LIPASE;

ANIMAL; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LEGAL ASPECT; METHODOLOGY; PARKINSON DISEASE; PERIPHERAL VASCULAR DISEASE; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOPROTEIN LIPASE; MUSCULAR DYSTROPHY, DUCHENNE; PARKINSON DISEASE; PERIPHERAL VASCULAR DISEASES; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 80052321503     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-095-9_2     Document Type: Chapter

References (77)

1. Cohen, S., Chang, A., Boyer, H. and Helling, R. (1973) Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 70, 3240–3244.
2. Friedmann, T. (ed.) (1999) The development of Human gene therapy, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
3. Friedmann, T. (1983) Gene Therapy Facts and fictions in Biology’s New Approaches to disease., pp. 91-96, (ed. Friedmann, T.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
4. Rosenberg, S., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R., and Moen, R. (1990) Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578.
5. Blaese, R.M., Culver, K.W., Miller, A.D., Carter, C.S., Fleisher, T., Clerici, M., et al. (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475–480.
6. Trent, R.J. and Alexander, I.E. (2004) Gene therapy: applications and progress towards the clinic. Intern. Med. J. 34, 621–625.
7. Gene Therapy Clinbical Trials Worlwide. in The Journal of Gene Medicine (Eds Wiley et al, Interscience, 2009).
8. Tsurumi, C., Shimizu, Y., Saeki, M., Kato, S., Demartino, G.N., Slaughter, C.A., et al. (1996) cDNA cloning and functional analysis of the p97 subunit of the 26S proteasome, a polypeptide identical to the type-1 tumor-necrosisfactor-receptor-associated protein-2/55.11. Eur. J. Biochem. 239, 912–921.
9. King, N.M. and Cohen-Haguenauer, O. (2008) En route to ethical recommendations for gene transfer clinical trials. Mol. Ther. 16, 432–438.
10. Nash, P., Whitty, A., Handwerker, J., Macen, J., and McFadden, G. (1998) Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J. Biol. Chem. 273, 20982–20991.
11. Foster, K., Foster, H., and Dickson, J.G. (2006) Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther. 13, 1677–1685.
12. Tosi, M.F., van Heeckeren, A., Ferkol, T.W., Askew, D., Harding, C.V., and Kaplan, J.M. (2004) Effect of Pseudomonas-induced chronic lung inflammation on specific cytotoxic T-cell responses to adenoviral vectors in mice. Gene Ther. 11, 1427–1433.
13. Moss, R.B., Rodman, D., Spencer, L.T., Aitken, M.L., Zeitlin, P.L., Waltz, D., et al. (2004) Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125, 509–521.
14. Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J.F., Chamberlain, J.S., et al. (2005) Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol. 23, 1435–1439.
15. Flotte, T.R., Zeitlin, P.L., Reynolds, T.C., Heald, A.E., Pedersen, P., Beck, S., et al. (2003) Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 14, 1079–1088.
16. http://clinicaltrials.gov/ct2/show/study/NCT00073463. Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis. This study has been terminated. In ClinicalTrials.gov (2010).
17. Croteau, G.A., Martin, D.B., Camp, J., Yost, M., Conrad, C., Zeitlin, P.L., et al. (2004) Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis. Ann. Occup. Hyg. 48, 673–681.
18. Medina, M.F., Kobinger, G.P., Rux, J., Gasmi, M., Looney, D.J., Bates, P., et al. (2003) Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol. Ther. 8, 777–789.
19. Sinn, P.L., Shah, A.J., Donovan, M.D., and McCray, P.B., Jr. (2005) Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am. J. Respir. Cell Mol. Biol. 32, 404–410.
20. Krause, D.S., Theise, N.D., Collector, M.I., Henegariu, O., Hwang, S., Gardner, R., et al. (2001) Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105, 369–377.
21. Kotton, D.N., Fabian, A.J., and Mulligan, R.C. (2005) Failure of bone marrow to reconstitute lung epithelium. Am. J. Respir. Cell Mol. Biol. 33, 328–334.
22. Macpherson, H., Keir, P., Webb, S., Samuel, K., Boyle, S., Bickmore, W., et al. (2005) Bone marrow-derived SP cells can contribute to the respiratory tract of mice in vivo. J. Cell Sci. 118, 2441–2450.
23. Desigaux, L., Gourden, C., Bello-Roufai, M., Richard, P., Oudrhiri, N., Lehn, P., et al. (2005) Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum. Gene Ther. 16, 821–829.
24. Pringle I., Davies L., McLachlan G., Collie D., Gill D. et al. (2004) Duration of reporter gene expression from naked pDNA in the mouse lung following direct electroporation and development of wire electrodes for sheep lung electroporation studies. Mol. Ther. 9, S56.
25. Xenariou S., Liang H., Griesenbach U., Farley R., Somerton L. et al. (2005) Sonoporation increases non-viral gene transfer to the murine lung. Mol. Ther. 11, S139.
26. Norez, C., Antigny, F., Noel, S., Vandebrouck, C., and Becq, F. (2009) A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am. J. Respir. Cell Mol. Biol. 41, 217–225.
27. Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M., and Kunkel, L.M. (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646–650.
28. Alexander, B.L., Ali, R.R., Alton, E.W., Bainbridge, J.W., Braun, S., Cheng, S.H., et al. (2007) Progress and prospects: gene therapy clinical trials (part 1). Gene Ther. 14, 1439–1447.
29. Romero, N.B., Braun, S., Benveniste, O., Leturcq, F., Hogrel, J.Y., Morris, G.E., et al. (2004) Phase I study of dystrophin plasmidbased gene therapy in Duchenne/Becker muscular dystrophy. Hum. Gene Ther. 15, 1065–1076.
30. Takeshima, Y., Yagi, M., Wada, H., Ishibashi, K., Nishiyama, A., Kakumoto, M., et al. (2006) Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59, 690–694.
31. Chamberlain, J.S. (2002) Gene therapy of muscular dystrophy. Hum. Mol. Genet. 11, 2355–2362.
32. Rafael, J.A. and Brown, S.C. (2000) Dystrophin and utrophin: genetic analyses of their role in skeletal muscle. Microsc. Res. Tech. 48, 155–166.
33. Le Bourdelles, B., Horellou, P., Le Caer, J.P., Denefle, P., Latta, M., Haavik, J., et al. (1991) Phosphorylation of human recombinant tyrosine hydroxylase isoforms 1 and 2: an additional phosphorylated residue in isoform 2, generated through alternative splicing. J. Biol. Chem. 266, 17124–17130.
34. Li, S., Kimura, E., Ng, R., Fall, B.M., Meuse, L., Reyes, M., et al. (2006) A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Hum. Mol. Genet. 15, 1610–1622.
35. Rodino-Klapac, L.R., Janssen, P.M., Montgomery, C.L., Coley, B.D., Chicoine, L.G., Clark, K.R., et al. (2007) A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J. Transl. Med. 5, 45.
36. Mingozzi, F. and High, K.A. (2007) Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316–324.
37. Wang, Z., Storb, R., Lee, D., Kushmerick, M.J., Chu, B., Berger, C., et al. (2009) Immune Responses to AAV in Canine Muscle Monitored by Cellular Assays and Noninvasive Imaging. Mol. Ther. 18, 617–624.
38. Cooper, M., Nayak, S., Hoffman, B.E., Terhorst, C., Cao, O., and Herzog, R.W. (2009) Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum. Gene Ther. 20, 767–776.
39. Hoen, P.A., de Meijer, E.J., Boer, J.M., Vossen, R.H., Turk, R., Maatman, R.G., et al. (2008) Generation and characterization of transgenic mice with the full-length human DMD gene. J. Biol. Chem. 283, 5899–5907.
40. Evans, J.R. and Barker, R.A. (2008) Neurotrophic factors as a therapeutic target for Parkinson’s disease. Expert Opin. Ther. Targets 12, 437–447.
41. Laguna Goya, R., Tyers, P., and Barker, R.A. (2008) The search for a curative cell therapy in Parkinson’s disease. J. Neurol. Sci. 265, 32–42.
42. Palfi, S. (2008) Towards gene therapy for Parkinson’s disease. Lancet Neurol. 7, 375–376.
43. Herzog, C.D., Brown, L., Gammon, D., Kruegel, B., Lin, R., Wilson, A., et al. (2009) Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson’s disease. Neurosurgery 64, 602–12; discussion 612–613.
44. Coelho, M., Ferreira, J., Rosa, M., and Sampaio, C. (2008) Treatment options for non-motor symptoms in late-stage Parkinson’s disease. Expert Opin. Pharmacother. 9, 523–535.
45. Cavazzana-Calvo, M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon, E., Nusbaum P., et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672.
46. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., et al. (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410–2413.
47. Hacein-Bey-Abina, S. Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419.
48. (ESGT), E.S.G.T. (Press release January, 2003).
49. Rabbitts, T.H., Axelson, H., Forster, A., Grutz, G., Lavenir, I., Larson, R., et al. (1997) Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis. Leukemia 11 Suppl 3, 271–272.
50. Nam, C.H. and Rabbitts, T.H. (2006) The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol. Ther. 13, 15–25.
51. Pike-Overzet, K., de Ridder, D., Weerkamp, F., Baert, M., Verstegen, M., Brugmann, M., et al. (2006) Gene therapy: is IL2RG oncogenic in T-cell development? Nature 443, E5.
52. Cavazzana-Calvo, M. and Fischer, A. (2007) Gene therapy for severe combined immunodeficiency: are we there yet? J. Clin. Invest. 117, 1456–1465.
53. Notarangelo, L., Miao, C., and Ochs, H. (2008) Wiskott-Aldrich syndrome. Curr. Opin. Hematol. 15, 30–36.
54. Westerberg, L.S., de la Fuente, M.A., Wermeling, F., Ochs, H.D., Karlsson, M.C., Snapper, S.B., et al. (2008) WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function. Blood 112, 4139–4147.
55. Marangoni, F., Bosticardo, M., Charrier, S., Draghici, E., Locci, M., Scaramuzza, S., et al. (2009) Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol. Ther. 17, 1073–1082.
56. Dewey, R.A., Avedillo Diez, I., Ballmaier, M., Filipovich, A., Greil, J., Gungor, T., et al. (2006) Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. Exp. Hematol. 34, 1161–1169.
57. Mantovani, J., Charrier, S., Eckenberg, R., Saurin, W., Danos, O., Perea, J., et al. (2009) Diverse genomic integration of a lentiviral vector developed for the treatment of WiskottAldrich syndrome. J. Gene Med. 11, 645–654.
58. Charrier, S., Stockholm, D., Seye, K., Opolon, P., Taveau, M., Gross, D.A., et al. (2005) A lentiviral vector encoding the human WiskottAldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther. 12, 597–606.
59. Galy, A., Roncarolo, M.G., and Thrasher, A.J. (2008) Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin. Biol. Ther. 8, 181–190.
60. Excoffon, K.J., Liu, G., Miao, L., Wilson, J.E., McManus, B.M., Semenkovich, C.F., et al. (1997) Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 17, 2532–2539.
61. Liu, G., Excoffon, K.J., Benoit, P., Ginzinger, D.G., Miao, L., Ehrenborg, E., et al. (1997) Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Hum. Gene Ther. 8, 205–214.
62. Liu, G., Excoffon, K.J., Wilson, J.E., McManus, B.M., Miao, L., Benoit, P., et al. (1998) Enhanced lipolysis in normal mice expressing liver-derived human lipoprotein lipase after adenoviral gene transfer. Clin. Invest. Med. 21, 172–185.
63. Rip, J., van Dijk, K.W., Sierts, J.A., Kastelein, J.J., Twisk, J., and Kuivenhoven, J.A. (2006) AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim. Biophys. Acta 1761, 1163–1168.
64. Vaessen, S.F., Twisk, J., Kastelein, J.J., and Kuivenhoven, J.A. (2007) Gene therapy in disorders of lipoprotein metabolism. Curr. Gene Ther. 7, 35–47.
65. Fox, J.C. and Swain, J.L. (1996) Angiogenic gene therapy. A leg to stand on? Circulation 94, 3065–3066.
66. Takeshita, S., Zheng, L.P., Asahara, T., Reissen, R., Brogi, E., Ferrara, N., et al. (1993) In vivo evidence of enhanced angiogenesis following direct arterial transfer of the plasmid encoding vascular endothelial growth factor. Circulation 88 (suppl I), I-476, abstract.
67. Takeshita, S., Zheng, L.P., Brogi, E., Kearney, M., Pu, L.Q., Bunting, S., et al. (1994) Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662–670.
68. Feldman, L.J., Tahlil, O., and Steg, P.G. (1996) Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives. Semin. Interv. Cardiol. 1, 203–208.
69. Tsurumi, Y., Takeshita, S., Chen, D., Kearney, M., Rossow, S.T., Passeri, J., et al. (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94, 3281–3290.
70. Caron, A., Michelet, S., Sordello, S., Ivanov, M.A., Delaere, P., Branellec, D., et al. (2004) Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J. Gene Med. 6, 1033–1045.
71. Witzenbichler, B., Mahfoudi, A., Soubrier, F., Le Roux, A., Branellec, D., Schultheiss, H.P., et al. (2006) Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J. Mol. Med. 84, 491–502.
72. Comerota, A.J., Throm, R.C., Miller, K.A., Henry, T., Chronos, N., Laird, J., et al. (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J. Vasc. Surg. 35, 930–936.
73. Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114–1123.
74. Nikol, S., Baumgartner, I., Van Belle, E., Diehm, C., Visona, A., Capogrossi, M.C., et al. (2008) Therapeutic angiogenesis with intramuscular NV1FGF improves amputationfree survival in patients with critical limb ischemia. Mol. Ther. 16, 972–978.
75. Baumgartner, I., Chronos, N., Comerota, A., Henry, T., Pasquet, J.P., Finiels, F., et al. (2009) Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol. Ther. 17, 914–921.
76. Keo, H., Hirsch, A., Baumgartner, I., Nikol, S., and Henry, T. (2009) Gene Therapy in Critical Limb Ischemia. Vascular Disease Management 6, 118–124.
77. Ruck, A. and Sylven, C. (2008) Therapeutic angiogenesis gains a leg to stand on. Mol. Ther. 16, 808–810.